Real‐world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database

🥉 Top 5% JournalFeb 25, 2025Diabetes, obesity & metabolism

Use and effectiveness of tirzepatide in people without type 2 diabetes

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

The overall cohort included 20,998 individuals with a mean BMI of 36.9 kg/m.

66.0% of individuals in the cohort had at least one obesity-related complication.
Persistence with tirzepatide in the utilization cohort was 55.4%.
By the sixth prescription fill, 74.2% of individuals were on less than 10 mg of tirzepatide.
Mean weight reduction at 6 months post-index was 11.9%, with 85.8% of individuals achieving at least a 5% reduction.
61.5% of individuals experienced a weight reduction of at least 10%.

AI simplified

AIMS: To understand real-world tirzepatide utilization and effectiveness (change in weight and body mass index [BMI]) among people without type 2 diabetes (T2D) in the United States.

MATERIALS AND METHODS: This retrospective, observational study used Optum's de-identified Market Clarity database (index date: first-observed tirzepatide claim; index period: 13 May 2022-30 September 2023). Outcomes were assessed in 3 cohorts: (1) Overall cohort: age ≥18 years; ≥1 tirzepatide claim; no baseline T2D diagnosis codes, anti-diabetes medication use (except metformin) or glycated haemoglobin ≥6.5%; continuous medical and pharmacy enrolment for ≥12 months pre-index. (2) Utilization cohort: all above criteria and anti-obesity medication (AOM)-eligible individuals (BMI ≥30 kg/m, or ≥27 kg/mwith ≥1 obesity-related complication [ORC]) for assessment of tirzepatide utilization (persistence, discontinuation, dose escalation and switching 6 months post-index). (3) Effectiveness cohort: all above criteria and AOM-eligible glucagon-like peptide-1 receptor agonist (GLP-1 RA)-naive individuals persistent on tirzepatide for ≥6 months with pre- and post-index weight and BMI measurements for assessment of tirzepatide effectiveness (mean absolute and percent bodyweight/BMI change from baseline and bodyweight/BMI reduction ≥5%, ≥10%, ≥15% and ≥20%). All analyses were descriptive. 2 2

RESULTS: Overall cohort included 20,998 individuals (mean age: 47.4 years, female: 74.9%, mean BMI: 36.9 kg/m). At index, 66.0% of individuals had ≥1 ORC, while 44.4% had ≥2 ORCs. Persistence in the utilization cohort was 55.4%; 30.8% switched to a different AOM/GLP-1 RA analogue or restarted tirzepatide after discontinuation, and by the sixth prescription fill, 74.2% were on <10 mg tirzepatide. Mean weight reduction in the effectiveness cohort was 11.9% at 6 months post-index (≥5%: 85.8%; ≥10%: 61.5%). 2

CONCLUSIONS: Real-world evidence suggests multimorbidity is common among tirzepatide initiators. While tirzepatide dose escalation was slower than in clinical trials, individuals achieved weight reduction at 6 months, consistent with clinical trials.

Key numbers

11.9%

Weight Reduction

Mean weight reduction at 6 months post-index in the effectiveness cohort.

55.4%

Persistence Rate

Proportion of individuals in the utilization cohort who continued tirzepatide after 6 months.

66.0%

Initiators with Complications

Proportion of individuals in the overall cohort with at least one obesity-related complication.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text ↗

Abstract

Key numbers

Full Text

Related papers